ImCheck Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
47
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.25B
ImCheck Therapeutics General Information
Description
Developer of immuno-modulatory antibodies designed for treating cancer and other immune-related diseases. The company's antibodies offer immunotherapeutics for severe unmet medical needs with a primary focus on immuno-oncology and a proprietary know-how in butyrophilin biology, a focused therapeutic pipeline and strategic regulatory designations, enabling cancer and autoimmune disease researchers and healthcare providers to access novel immune-modulation treatments.
Contact Information
Website
www.imchecktherapeutics.com(Operating Subsidiary)
Corporate Office
- 31 Chemin Joseph Aiguier
- CS 70071, Cedex 09
- 13402 Marseille
- France
Corporate Office
- 31 Chemin Joseph Aiguier
- CS 70071, Cedex 09
- 13402 Marseille
- France
ImCheck Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 15-Dec-2025 | $1.25B | Completed | Generating Revenue | ||
| 11. Grant | 29-Aug-2024 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 9. Accelerator/Incubator | 01-Aug-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 10-Jun-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 15-Sep-2020 | Completed | Generating Revenue | |||
| 6. Grant | 01-Aug-2019 | Completed | Generating Revenue | |||
| 5. Grant | 23-Apr-2019 | Completed | Generating Revenue | |||
| 4. Grant | 10-Oct-2017 | $1.1M | $24.1M | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A) | 02-May-2017 | $21.5M | $24.1M | Completed | Generating Revenue |
ImCheck Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| A Shares | 49,164 | $1.062015 | $212.4 | $212.4 | 1x | $212.4 | 8.72% | |
| A Shares | 14,584 | $1.062015 | $169.92 | $169.92 | 1x | $169.92 | 2.59% |
ImCheck Therapeutics Comparisons
Industry
Financing
Details
ImCheck Therapeutics Competitors (35)
One of ImCheck Therapeutics’s 35 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
ImCheck Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImCheck Therapeutics Patents
ImCheck Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4731681-A1 | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis | Pending | 23-Jun-2023 | ||
| JP-2026523584-A | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis | Pending | 23-Jun-2023 | ||
| US-20260265379-A1 | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis | Pending | 23-Jun-2023 | ||
| WO-2024261239-A1 | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis | Inactive | 23-Jun-2023 | ||
| AU-2024260225-A1 | Methods for treating multidrug resistant bacterial infections | Pending | 27-Apr-2023 | C07K16/2827 |
ImCheck Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ImCheck Therapeutics Former Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Agent Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority |
ImCheck Therapeutics FAQs
-
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015.
-
Where is ImCheck Therapeutics headquartered?
ImCheck Therapeutics is headquartered in Marseille, France.
-
What is the size of ImCheck Therapeutics?
ImCheck Therapeutics has 47 total employees.
-
What industry is ImCheck Therapeutics in?
ImCheck Therapeutics’s primary industry is Drug Discovery.
-
Is ImCheck Therapeutics a private or public company?
ImCheck Therapeutics is a Private company.
-
What is the current valuation of ImCheck Therapeutics?
The current valuation of ImCheck Therapeutics is .
-
What is ImCheck Therapeutics’s current revenue?
The current revenue for ImCheck Therapeutics is .
-
How much funding has ImCheck Therapeutics raised over time?
ImCheck Therapeutics has raised $190M.
-
Who are ImCheck Therapeutics’s investors?
Agent Capital, Alexandria Venture Investments, Andera Partners, Boehringer Ingelheim Venture Fund, and Bpifrance are 5 of 21 investors who have invested in ImCheck Therapeutics.
-
Who are ImCheck Therapeutics’s competitors?
NGM Biopharmaceuticals, Attune Pharmaceuticals, Sangamo Therapeutics, Altimmune, and Immunocore Holdings are some of the 35 competitors of ImCheck Therapeutics.
-
When was ImCheck Therapeutics acquired?
ImCheck Therapeutics was acquired on 15-Dec-2025.
-
Who acquired ImCheck Therapeutics?
ImCheck Therapeutics was acquired by Ipsen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
